Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a ...

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than ...

Moderna is investing more than $140 million to bring drug manufacturing to its Massachusetts campus, a move that it says will ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Moderna will invest $140 million in expanding its U.S. manufacturing capacity and onshoring its drug manufacturing to its existing facility in Norwood, Mass. The company said it will now operate full ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...